Business Context and Reporting Period
Company: Molina Healthcare, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 17, 2025
Event: Announcement of a private offering of senior notes and the restructuring of its credit facility.
Key Financial Metrics
The filing provides historical and trailing twelve-month (TTM) financial data to support the debt offering. All figures are in millions unless otherwise noted.
| Metric | Year Ended Dec 31, 2022 | Year Ended Dec 31, 2023 | Year Ended Dec 31, 2024 | TTM Ended Sep 30, 2025 |
|---|---|---|---|---|
| Net Income | $792 | $1,091 | $1,179 | $883 |
| EBITDA | $1,349 | $1,744 | $1,893 | $1,522 |
| Adjusted EBITDA | $1,709 | $1,934 | $2,091 | $1,634 |
| Interest Expense | $110 | $109 | $118 | $174 |
Debt and Liquidity: The Company currently has no borrowings outstanding under its Existing Credit Facility and maintains sufficient cash on its balance sheet. It intends to issue $750 million in senior notes due 2031.
Material Changes and Strategic Actions
- Senior Notes Offering: The Company intends to privately offer $750 million in aggregate principal amount of senior notes due 2031 to qualified institutional buyers and non-U.S. persons.
- Use of Proceeds: Net proceeds will be used to repay outstanding delayed draw term loans under the Existing Credit Facility.
- Credit Facility Restructuring: Following the repayment of term loans, the Company plans to terminate the Existing Credit Facility and replace it with a New Credit Facility. The new facility will be undrawn at closing, fully available for general corporate purposes, and expected to include covenant amendments favorable to the Company.
- Performance Trend: Adjusted EBITDA for the twelve months ended September 30, 2025 ($1,634 million) represents a decrease from the full year 2024 ($2,091 million).
Guidance, Risks, and Unusual Items
Forward-Looking Statements: The Company cautions that there can be no assurance it will complete the Offering or replace the Existing Credit Facility. Success is subject to market conditions and the satisfaction of closing conditions.
Non-GAAP Adjustments: The filing details specific adjustments made to calculate Adjusted EBITDA:
- 2023: Included a non-recurring credit loss on 2022 Marketplace risk adjustment receivables due to the insolvency of an issuer in the Texas risk pool, plus litigation costs and termination benefits.
- 2024 & 2025 (YTD): Adjustments include non-recurring litigation costs and one-time termination benefits.
- Impairment Charges: A $208 million impairment charge in 2022 was attributable to the plan to reduce the leased real estate footprint. No impairment charges were recorded in subsequent periods presented.
Limitations: The Company notes that EBITDA and Adjusted EBITDA do not reflect cash requirements for capital expenditures, working capital, or debt service.
Investor Verification Checklist
- Confirm the final closing terms and interest rate of the $750 million senior notes due 2031.
- Verify the specific covenant amendments in the New Credit Facility compared to the Existing Credit Facility.
- Review the detailed breakdown of "non-recurring litigation costs" included in the Adjusted EBITDA adjustments for 2024 and 2025.
- Assess the impact of the Texas risk pool insolvency on future risk adjustment receivables.
- Monitor the Company's cash balance to ensure it remains sufficient to fund operations while the credit facility is undrawn.